NEW YORK (GenomeWeb) – Germany's BioNTech Diagnostics and Shuwen Biotech said today that they have signed a deal to commercialize BioNTech's molecular breast cancer stratification test MammaTyper in China.

According to BioNTech, MammaTyper is a CE-IVD marked test that measures expression levels of four genes in breast cancer tissue via RT-qPCR in order to stratify tumor samples into four subtypes: luminal A-like, luminal B-like/HER2 negative, luminal B-like/HER2 positive, HER2 positive/non-luminal, and triple-negative/ductal.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.